戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 on and driving fibrotic sequelae after acute viral pneumonia.
2 thy participants and participants with other viral pneumonia.
3 s was limited by lack of a gold standard for viral pneumonia.
4 ptomatic, symptomatic without pneumonia, and viral pneumonia.
5 structive pulmonary disease exacerbations or viral pneumonia.
6         Death occurred in one patient due to viral pneumonia.
7 ourse of COVID-19 with high fever and severe viral pneumonia.
8 in of influenza A virus caused fatal primary viral pneumonia.
9 ignificant impact on the course of influenza viral pneumonia.
10 reduce maternal morbidity and mortality from viral pneumonia.
11 immune responses, and pathologic evidence of viral pneumonia.
12 ral immunity and were unable to control this viral pneumonia.
13 anism used by CD8+ T cells to terminate this viral pneumonia.
14 reovirus type 1 Lang (T1L) in a rat model of viral pneumonia.
15 fective in distinguishing M. pneumoniae from viral pneumonia.
16 s presenting with more flu-like symptoms and viral pneumonia.
17 guish between patients with bacterial versus viral pneumonia.
18 pport on their first ICU day versus 65% with viral pneumonia.
19 cally mitigated lung pathology, and prevents viral pneumonia.
20 onavirus disease (p = 0.064) versus 64.1 for viral pneumonia.
21 onia, and 50 had noncoronavirus disease 2019 viral pneumonia.
22 LF of patients with bacterial as compared to viral pneumonia.
23 scade of cardiovascular complications beyond viral pneumonia.
24 y distress syndrome may be slower than other viral pneumonia.
25 spiratory failure and 189 (8.7%) experienced viral pneumonia.
26  2019 in comparison with patients with other viral pneumonias.
27 ombosis compared with noncoronavirus disease viral pneumonias.
28  membrane oxygenation in comparison to other viral pneumonias.
29 iac arrhythmias (15.0%; 95% CI, 8.1%-21.7%), viral pneumonia (13.3%; 95% CI, 6.5%-20.1%), and respira
30  stent manipulation (2), meningitis (1), and viral pneumonia (3/5).
31 nger in coronavirus disease (10.4 d) than in viral pneumonia (4.3 d) patients, except in the viral pn
32 al pneumonia (4.3 d) patients, except in the viral pneumonia-acute respiratory distress syndrome subg
33 erial pneumonia (aHR, 2.8; 95% CI, 2.0-3.9), viral pneumonia (aHR, 1.5; 95% CI, 1.1-2.1), fungal pneu
34               This risk, however, was due to viral pneumonia alone (HR, 3.94; P < 0.01), without sign
35 t rates similar to practices in pre-COVID-19 viral pneumonia, although later during the course of ECM
36         The most common causes of death were viral pneumonia and acute respiratory distress syndrome.
37  syncytial virus (RSV) is a leading cause of viral pneumonia and bronchiolitis during the first 6 mon
38  syncytial virus (RSV) is a leading cause of viral pneumonia and bronchiolitis during the first six m
39                                              Viral pneumonia and immunolocalization of viral antigen
40 equences of viruses known to cause childhood viral pneumonia and myocarditis.
41 ondrial DNA was elevated in individuals with viral pneumonia and sepsis secondary to coronavirus dise
42 robable tuberculosis, 50% (kappa, 0.002) for viral pneumonia, and 56% (kappa, 0.06) for bacterial pne
43 yptococcus or Nocardia, bacterial pneumonia, viral pneumonia, and Kaposi's sarcoma.
44 including ischemiasolidusreperfusion injury, viral pneumonia, and renal failure.
45 danger of secondary bacterial involvement in viral pneumonia, and suggests mechanisms that may contri
46 ently emerged causing an ongoing outbreak of viral pneumonia around the world.
47 ere acute respiratory syndrome coronavirus 2 viral pneumonia, bacterial pneumonia, and multiple traum
48 ere acute respiratory syndrome coronavirus 2 viral pneumonia, bacterial pneumonia, and trauma cohorts
49 re patients were mobilized with pre-COVID-19 viral pneumonia, but receipt of a tracheostomy during EC
50  of tracheostomy was similar in pre-COVID-19 viral pneumonia, but tracheostomies were performed 3 day
51              In this setting, using the term viral pneumonia can be a reasonable and inclusive altern
52                         We hypothesized that viral pneumonia can be treated effectively if both virus
53 rs significant regenerative capacity, severe viral pneumonia can chronically impair lung function by
54 ists blindly evaluated 220 chest CT scans of viral pneumonia cases (n = 151 COVID-19; n = 69 other vi
55 sions and for disease diagnosis can identify viral pneumonia caused by coronavirus disease 2019 (COVI
56  severity, and can also discriminate between viral pneumonia caused by COVID-19 and other types of pn
57 nspecific pneumonia, interstitial pneumonia, viral pneumonia, consolidation, or nonspecific interstit
58       Compared to ARDS due to other types of viral pneumonia, COVID-19 is characterized by impaired i
59                                              Viral pneumonia did, however, significantly increase the
60 ntified as the causal agent for the pandemic viral pneumonia disease, COVID-19.
61 ions exhibited decreased severity, and other viral pneumonia exhibited similar severity (OR, 0.88; 95
62                Of note, BA.2.75 causes focal viral pneumonia in hamsters, characterized by patchy inf
63 member of the Hantavirus genus, causes acute viral pneumonia in humans and is thought to persistently
64 incipal etiologic agent of bronchiolitis and viral pneumonia in infants and young children.
65 V) is the leading cause of bronchiolitis and viral pneumonia in infants and young children.
66 can serve as a model for the pathogenesis of viral pneumonia in which pulmonary inflammation results
67  (RSV) is a major cause of bronchiolitis and viral pneumonia in young children and a serious health r
68 , multicenter data comparing this with other viral pneumonias in those requiring extracorporeal membr
69                                    In severe viral pneumonia, including Coronavirus disease 2019 (COV
70 RDS) is a major cause of mortality in severe viral pneumonia, including COVID-19.
71 course of the disease and overlap with other viral pneumonias, including influenza pneumonia.
72                   With respect to CARV, only viral pneumonia increased the risk of both CLAD and graf
73 nic bronchopneumonia in swine, potentiates a viral pneumonia induced by the porcine reproductive and
74 for acute respiratory failure resulting from viral pneumonia is associated with improved mortality co
75                        In a murine influenza viral pneumonia model, B-catenin-mediated AM inflammator
76 these patients, there were 51 (27%) cases of viral pneumonia, of which nine cases were due to acute v
77         Fifty-seven (57%) patients developed viral pneumonia, of whom 20 (20%) required supplemental
78                  57 (57%) patients developed viral pneumonia, of whom 20 (20%) required supplemental
79 ized across settings, discriminating between viral pneumonia, other types of pneumonia and the absenc
80 ological agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease 2019 (CO
81 r coronavirus disease 2019 patients than for viral pneumonia patients admitted to ICU.
82                              A subset of 202 viral pneumonia patients with concurrent acute respirato
83 ength of stay, comparable with the subset of viral pneumonia patients with concurrent acute respirato
84 of stay were 3.1 and 3.0 days longer than in viral pneumonia patients.
85 avirus disease group versus 0.95 and 0.94 in viral pneumonia patients.
86 us disease patients and 0.82 (0.75-0.90) for viral pneumonia patients.
87 myelitis optica spectrum disorder attack and viral pneumonia related to COVID-19), all of which were
88 ibitors effectively lessened the severity of viral pneumonia, septic shock, colitis, and cytokine-dri
89 egulation in the lower airways during severe viral pneumonia that is distinct from lower airway respo
90 HPs inoculated by the i.b. route developed a viral pneumonia that likely exacerbated disease progress
91  a mycoplasma species acting to potentiate a viral pneumonia was developed.
92                                              Viral pneumonia was diagnosed in 10 (5 influenza and 5 p
93  using viral load of URT specimens to define viral pneumonia was equivocal.
94 ibuted to the death of Tg+ mice, even though viral pneumonia was present.
95 urrence of multiple episodes of viral RTI or viral pneumonia was significantly associated with a high
96                Lung abnormalities typical of viral pneumonias were common among deceased COVID-19+ in
97        Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-path
98 vascular homeostasis is a central feature of viral pneumonia, wherein endothelial cell (EC) death and
99 an manifest itself as airflow obstruction or viral pneumonia, which can be fatal.
100 nia, which requires antibiotic therapy, from viral pneumonia, which does not.
101                                              Viral pneumonia, which is typically associated with dise
102 enza virus infection (IVI) can cause primary viral pneumonia, which may progress to acute lung injury
103 lar rejection), and <25 days (euthanized for viral pneumonia with a functioning graft that showed his
104 en COVID-19 pneumonia and other viral or non-viral pneumonia with AUCs of 0.87-0.97.
105 e pulmonary disease during infancy following viral pneumonia with evidence of combined T and B cell i
106 nd differentiate those with bacterial versus viral pneumonia with high accuracy.
107 aged hosts at high risk of developing severe viral pneumonia with long-term impaired lung function.
108 cally, the initial stage is characterized by viral pneumonia with mild expression.
109 id and sensitive diagnostic tool in cases of viral pneumonia with or without myocarditis, and trachea
110 (SARS-CoV-2) infection and progress to acute viral pneumonia with profound lung tissue injury, recapi
111 te mycoplasma pneumonia from other bacterial/viral pneumonias with high accuracy (AUC: 0.84-0.95).
112 -CoV) is a zoonotic infection causing severe viral pneumonia, with index cases having resided in or r

 
Page Top